The New Drug Application (NDA) includes data from the Phase III studies OASIS 1, 2 and 3 - showing elinzanetant significantly reduced the frequency and severity of moderate to severe vasomotor symptoms over 12 weeks compared to placebo
Boehringer Ingelheim aims to develop this program as a potential key centerpiece component for its immuno-oncology portfolio
The acquisition will further strengthen Barentz’ position in India creating a leading life science distribution platform
GSK and Flagship to jointly fund up to $150 million upfront
Report highlights significant improvements in adolescent well-being in India
Dr. Reddy's Laboratories has reported total income of Rs. 7,672.7 crores during the period ended June 30, 2024
Giroctocogene fitelparvovec study meets primary and key secondary objectives of superiority compared to prophylaxis
Acquisition in line with Mankind’s stated objective to expand its presence in high entry barrier complex portfolios and high potential OTX brands
The partnership will significantly advance their sustainability initiatives by meeting around 67% of their power requirements for these plants
This strategic move aims to make Cupid's high-quality products more accessible to consumers nationwide
Subscribe To Our Newsletter & Stay Updated
